Advances in targeting cell surface signalling molecules for immune modulation

Sheng Yao, Yuwen Zhu, Lieping Chen

Research output: Contribution to journalArticlepeer-review

Abstract

The past decade has witnessed a surge in the development of immunomodulatory approaches to combat a broad range of human diseases, including cancer, viral infections, autoimmunity and inflammation as well as in the prevention of transplant rejection. Immunomodulatory approaches mostly involve the use of monoclonal antibodies or recombinant fusion proteins that target cell surface signalling molecules on immune cells to drive immune responses towards the desired direction. Advances in our understanding of the human immune system, along with valuable lessons learned from the first generation of therapeutic biologics, are aiding the design of the next generation of immunomodulatory biologics with better therapeutic efficacy, minimized adverse effects and long-lasting clinical benefit. The recent encouraging results from antibodies targeting programmed cell death protein 1 (PD1) and B7 homolog 1 (B7H1; also known as PDL1) for the treatment of various advanced human cancers show that immunomodulatory therapy has come of age.

Original languageEnglish (US)
Pages (from-to)130-146
Number of pages17
JournalNature Reviews Drug Discovery
Volume12
Issue number2
DOIs
StatePublished - Feb 2013
Externally publishedYes

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Fingerprint Dive into the research topics of 'Advances in targeting cell surface signalling molecules for immune modulation'. Together they form a unique fingerprint.

Cite this